Abstract：To investigate the molecular mechanisms of breast cancer resistance progression and develop novel potential therapeutic methods for the treatment of breast cancer resistance, in the study, the role of wtap in the cell migration of breast cancer MCF-7 and adriamycin resistant MCF-7/ADR cells were determined.MTT assays showed that adriamycin inhibited the survival of MCF-7 cells more than MCF-7/ADR did. qPCR and westernblot assays showed that WTAP was highly expressed in adriamycin resistant MCF-7/ADR cells. Moreover, transwell assays showed that increasing WTAP expression in MCF-7 cells had no effect on the migration of MCF-7 cells, whereas knocking down WTAP expression in MCF-7 /ADR cells can inhibit the migration of MCF-7/ADR cells, which may be affected by inhibiting epithelialmesenchymal transition (EMT) detected by westernblot. This finding will provide a new theoretical basis and strategy for the clinical treatment of breast cancer.
